Cushing’s Syndrome (CS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Cushing’s Syndrome (CS)

Cushing’s Syndrome (CS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

 

Cushing’s syndrome is a disorder that occurs when your body makes too much of the hormone cortisol over a long period of time. Cushing’s syndrome can be caused by overuse of cortisol medication, as seen in the treatment of chronic asthma or rheumatoid arthritis (iatrogenic Cushing’s syndrome), excess production of cortisol from a tumor in the adrenal gland or elsewhere in the body (ectopic Cushing’s syndrome) or a tumor of the pituitary gland secreting adrenocorticotropic hormone (ACTH) which stimulates the over-production of cortisol from the adrenal gland (Cushing’s disease).

Epidemiology-

According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses, pituitary ACTH-dependent Cushing's causes 68% to 72% of Cushing's syndrome. The reported incidence was 1.53 to 2.43 per million per year in European population-based studies and 6.3 to 7.3 per million person-years in the United States

Competitive landscape of Cushing’s Syndrome (CS) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Cushing’s Syndrome (CS) 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Cushing’s Syndrome (CS) market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

 

Read more: Cushing’s Syndrome (CS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No Asset Company Partner Phase
1 Korlym Corcept Therapeutics Inc. N/A Approved
2 Signifor Recordati SpA Novartis Approved
3 Ketoconazole HRA Pharma N/A Approved in Europe
4 Cytadren Novartis AG N/A Withdrawn from Market
5 Osilodrostat Recordati SpA Novartis NDA
6 Recorlev Strongbridge Biopharma plc N/A III
7 Relacorilant Corcept Therapeutics Inc. N/A III
8 Mifedren HRA Pharma N/A II/III
9 Nevanimibe Millendo Therapeutics, Inc. N/A II
10 Lysodren HRA Pharma N/A Investigator Initiated
11 Seliciclib Cyclacel Pharmaceuticals, Inc. ManRos Therapeutics Investigator Initiated
12 COR-005 Strongbridge Biopharma plc Evotec Development Outside U.S.
13 HTL0030310 Sosei Co., Ltd N/A Development Outside U.S.
14 ACTH Antagonist (Crinetics) Crinetics Pharmaceuticals, Inc. N/A Preclinical
15 Anti-ACTH XOMA Corporation N/A Preclinical
16 AP102 Amryt Pharma plc N/A Preclinical
17 BIM23B065 Ipsen SA N/A Preclinical
18 Steroidogenic factor-1 (SF-1) Antagonists Orphagen Pharmaceuticals N/A Preclinical